查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401898

2030年全球黑色素瘤診斷與治療市場預測：按癌症類型、診斷、治療、應用和地區進行全球分析

Melanoma Diagnostics and Therapeutics Market Forecasts to 2030 - Global Analysis By Cancer Type, By Diagnosis (Dermatoscopy, Blood Tests, Computed Tomography Scan and Other Diagnosis), Therapy, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球黑色素瘤診斷和治療市場在預測期內將以 17.1% 的複合年成長率成長。

黑色素瘤診斷涉及識別和評估黑色素細胞病變以診斷皮膚癌。技術包括皮膚鏡檢查、切片檢查和分析基因突變的分子測試。黑色素瘤的治療包括手術切除、免疫治療、標靶治療和化療。查核點抑制劑等免疫療法和針對特定基因變化的標靶治療正在發揮重要作用。早期檢測和個體化治療策略對於黑色素瘤的治療至關重要。

據美國癌症協會稱，預計2022年美國將新增約99,780例黑色素瘤病例，同年將有約7,650人死於黑色素瘤。

黑色素瘤增加

長期日曬、生活方式改變和遺傳傾向等因素導致全球黑色素瘤病例增加。發病率的迅速增加需要先進的診斷工具和治療性介入。宣傳宣傳活動和定期皮膚檢查的增加進一步增加了對早期發現和有效治療的需求。該行業對這些日益成長的健康問題的回應包括診斷和治療方面的持續創新，其中黑色素瘤盛行率的上升是市場擴張的關鍵驅動力。

治療費用高

與黑色素瘤的創新診斷、標靶治療和免疫療法相關的成本可能很高，限制了某些患者群體獲得治療的機會。這種財務障礙可能會阻礙及時和最佳的治療並影響患者的治療結果。此外，高成本對醫療保健系統造成負擔，給個人和付款人帶來經濟挑戰，並可能影響整體市場成長。

診斷技術的進步

高解析度成像技術、液體活體組織切片和分子分析等創新診斷工具可以實現黑色素瘤的早期、準確檢測。這些技術提高的敏感性和特異性有助於及時干預並改善患者的治療結果。此外，非侵入性和準確的診斷方法符合個人化醫療的成長趨勢，並促進量身定做的治療方法。這些技術進步不僅有助於早期診斷，而且在監測治療反應和疾病進展方面發揮重要作用。

專門醫療保健中心的數量有限

專業醫療中心數量有限是黑色素瘤診斷和治療市場的主要威脅。黑色素瘤通常需要專業知識才能進行準確的診斷和量身定做的治療計劃。缺乏此類中心會導致診斷延誤，阻礙獲得先進的治療性介入，並限制患者的治療效果。此外，患者可能面臨地理障礙，特別是在服務不足的地區，這會影響及時獲得關鍵診斷服務和尖端治療方法，導致市場擴張受到限制。

COVID-19 的影響：

COVID-19大流行對黑色素瘤診斷和治療市場產生了重大影響。醫療保健服務的中斷、資源的重新調整以及患者對前往醫療保健機構的恐懼導致黑色素瘤診斷和治療的延誤。然而，這場大流行凸顯了創新遠距醫療解決方案的重要性，並加速了遠端醫療和數位醫療技術的採用。

預計血液檢測領域在預測期內將是最大的。

由於血液檢測的非侵入性和對黑色素瘤相關生物標記的有效檢測，預計將成為黑色素瘤診斷市場中最大的部分。血液檢測為早期檢測提供了一種方便易行的方法，可以及時進行干預。液體活體組織切片技術的進步和循環腫瘤標記的鑑定正在促進該領域的興起。隨著對準確和微創診斷方法的需求增加，血液檢測領域預計將佔據主導地位，以滿足有效黑色素瘤檢測和監測日益成長的需求。

預計放射治療產業在預測期內複合年成長率最高。

預計放射線治療領域黑色素瘤診斷和治療市場將出現良好成長。這種成長是由於擴大採用放射療法作為黑色素瘤的有效治療選擇。強度調控放射治療(IMRT) 和立體定位放射線手術等放射治療技術的進步有助於提高準確性並減少副作用。人們越來越重視將放射治療涵蓋綜合治療策略的聯合治療，這也推動了放射治療的需求。

佔有率最大的地區

由於先進的醫療基礎設施、黑色素瘤患者的高盛行率以及活躍的研發活動，預計北美將在黑色素瘤診斷和治療市場中佔據最大的市場佔有率。此外，意識的提高、創新診斷技術的早期採用以及主要市場參與者的存在也有助於北美的主導地位。此外，有利的報銷政策、積極的法規環境以及對個人化醫療的關注進一步支持了該地區的市場領導地位。

複合年成長率最高的地區：

預計亞太地區黑色素瘤診斷和治療市場的成長率最高。這是由於人們認知的提高、醫療基礎設施的改善、可支配收入的增加以及人口高齡化導致黑色素瘤發病率上升。此外，該地區主要經濟體醫療保健技術的進步、研究舉措的擴大以及對個人化醫療的關注正在進一步推動對先進診斷和治療的需求。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球黑色素瘤診斷與治療市場：按癌症類型

  • 末期雀斑樣黑色素瘤
  • 黑色素瘤 黑色素瘤
  • 香菇黑色素瘤
  • 結節性黑色素瘤
  • 表淺黑色素瘤
  • 其他類型的癌症

第6章全球黑色素瘤診斷與治療市場：依診斷分類

  • 皮膚鏡檢查
  • 驗血
  • 電腦斷層掃描 (CT) 掃描
  • 前哨淋巴結活體組織切片
  • 超音波
  • X光
  • 其他診斷

第7章全球黑色素瘤診斷與治療市場：依治療分類

  • 化療
  • 生物療法
  • 免疫療法
  • 放射線治療
  • 標靶治療
  • 其他治療

第8章全球黑色素瘤診斷與治療市場：依應用分類

  • 診斷中心
  • 醫院
  • 醫療機構
  • 其他用途

第9章全球黑色素瘤診斷與治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • Abbott Diagnostics
  • Agilent Technologies
  • Amgen, Inc.
  • AstraZeneca
  • Biomerieux SA
  • Bristol Myers Squibb
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Dermlite
  • DermTech
  • Eli Lilly and Company
  • Roche Holding AG
  • GlaxoSmithKline PLC
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer, Inc.
  • Qiagen
  • Sanofi
Product Code: SMRC24418

According to Stratistics MRC, the Global Melanoma Diagnostics and Therapeutics Market is growing at a CAGR of 17.1% during the forecast period. Melanoma diagnostics involve the identification and assessment of melanocytic lesions to diagnose skin cancer. Techniques include dermoscopy, biopsy, and molecular testing to analyze genetic mutations. Therapeutics for melanoma comprise surgical excision, immunotherapy, targeted therapy, and chemotherapy. Immunotherapies like checkpoint inhibitors and targeted therapies addressing specific genetic alterations play a crucial role. Early detection and personalized treatment strategies are pivotal in managing melanoma.

According to the American Cancer Society, about 99,780 new melanomas will be diagnosed in the United States in 2022, and around 7,650 people are expected to die of melanoma in the same year.

Market Dynamics:

Driver:

Rising incidence of melanoma

Factors such as prolonged sun exposure, changing lifestyles, and genetic predispositions contribute to a rising number of melanoma cases globally. This surge in incidence necessitates advanced diagnostic tools and therapeutic interventions. Increased awareness campaigns and routine skin screenings further amplify the demand for early detection and effective treatments. The industry's response to this growing health concern involves continuous innovation in diagnostics and therapeutics, positioning the rising incidence of melanoma as a crucial driver fueling market expansion.

Restraint:

High treatment costs

The expenses associated with innovative diagnostics, targeted therapies, and immunotherapies for melanoma can be substantial, limiting accessibility for a portion of the patient population. This financial barrier hampers timely and optimal treatment, potentially impacting patient outcomes. Additionally, high costs may strain healthcare systems and result in economic challenges for both individuals and payers, impacting overall market growth.

Opportunity:

Advancements in diagnostic technologies

Innovative diagnostic tools, such as high-resolution imaging techniques, liquid biopsy assays, and molecular profiling, enable earlier and more accurate detection of melanoma. The enhanced sensitivity and specificity of these technologies contribute to timely interventions, improving patient outcomes. Moreover, non-invasive and precise diagnostic methods align with the growing trend of personalized medicine, facilitating tailored treatment approaches. These technological advancements not only aid in early diagnosis but also play a crucial role in monitoring treatment response and disease progression.

Threat:

Limited availability of specialized healthcare centers

The limited availability of specialized healthcare centers represents a significant threat to the melanoma diagnostics and therapeutics market. Melanoma often requires specialized expertise for accurate diagnosis and tailored treatment plans. The scarcity of such centers can lead to delays in diagnosis, hinder access to advanced therapeutic interventions, and limit patient outcomes. Additionally, patients may face geographical barriers, particularly in underserved regions, impacting timely access to crucial diagnostic services and cutting-edge therapies, which limits market expansion.

COVID-19 Impact:

The COVID-19 pandemic significantly impacted the melanoma diagnostics and therapeutics market. Disruptions in healthcare services, reprioritization of resources, and patients' concerns about visiting healthcare facilities led to delays in melanoma diagnosis and treatment. However, the pandemic underscored the importance of innovative and remote healthcare solutions, accelerating the adoption of telemedicine and digital health technologies.

The blood tests segment is expected to be the largest during the forecast period

The blood testing segment is expected to be the largest in the melanoma diagnostics market due to its non-invasive nature and efficiency in detecting biomarkers associated with melanoma. Blood-based tests offer a convenient and accessible means for early detection, enabling timely intervention. Advancements in liquid biopsy technologies and the identification of circulating tumor markers in blood contribute to the segment's prominence. As the demand for accurate, less invasive diagnostic methods grows, the blood testing segment is anticipated to dominate, catering to the increasing need for effective melanoma detection and monitoring.

The radiotherapy segment is expected to have the highest CAGR during the forecast period

The radiotherapy segment is projected to achieve lucrative growth in the melanoma diagnostics and therapeutics market. This growth is attributed to the increasing adoption of radiotherapy as an effective treatment option for melanoma. Technological advancements in radiotherapy techniques, including intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery, contribute to enhanced precision and reduced side effects. The growing emphasis on combination therapies, where radiotherapy is integrated into comprehensive treatment strategies, further propels the demand for radiotherapy.

Region with largest share:

North America is poised to command the largest market share in the melanoma diagnostics and therapeutics market due to its advanced healthcare infrastructure, a high prevalence of melanoma cases, and robust research and development activities. Moreover, increasing awareness, early adoption of innovative diagnostic technologies, and the presence of key market players contribute to North America's dominant position. Additionally, favorable reimbursement policies, a proactive regulatory environment, and a focus on personalized medicine further drive the region's leadership in the market.

Region with highest CAGR:

The Asia Pacific region is poised to experience the highest growth rate in the melanoma diagnostics and therapeutics market due to increasing awareness, improving healthcare infrastructure, rising disposable income, and a growing aging population that contribute to a higher prevalence of melanoma cases. Additionally, advancements in healthcare technologies, expanding research initiatives, and a focus on personalized medicine in key economies within the region further drive the demand for advanced diagnostics and therapeutics.

Key players in the market:

Some of the key players in Melanoma Diagnostics And Therapeutics Market include Abbott Diagnostics, Agilent Technologies, Amgen, Inc., AstraZeneca, Biomerieux SA, Bristol Myers Squibb, Caliber Imaging & Diagnostics, Inc., Canfield Scientific, Inc., Dermlite, DermTech, Eli Lilly and Company, Roche Holding AG, GlaxoSmithKline PLC, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Qiagen and Sanofi.

Key Developments:

In November 2023, The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

In November 2023, Amgen announced new data reinforcing the safety and efficacy of Repatha® (evolocumab) from the FOURIER Open Label Extension (OLE) [FOURIER-OLE] trial at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia. These presentations will focus on the reduction of a known cardiovascular disease (CVD) risk factor, LDL "bad" cholesterol (LDL-C). Amgen will also present new research from the Phase 2 OCEAN(a)-DOSE study of its investigational small interfering RNA (siRNA) olpasiran that will focus on a primarily genetically determined and presumed independent CVD risk factor, lipoprotein(a) [Lp(a)].

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.

Cancer Types Covered:

  • Acral Lentiginous Melanoma
  • Amelanotic Melanoma
  • Lentigno gna Melanoma
  • Nodular Melanoma
  • Superficial Spreading Melanoma
  • Other Cancer Types

Diagnosis Covered:

  • Dermatoscopy
  • Blood Tests
  • Computed Tomography (CT) Scan
  • Sentinel Lymph Node Biopsy
  • Ultrasound
  • X-Rays
  • Other Diagnosis

Therapies Covered:

  • Chemotherapy
  • Biological Therapy
  • Immune Therapy
  • Radiotherapy
  • Targeted Therapy
  • Other Therapies

Applications Covered:

  • Diagnostic Centers
  • Hospitals
  • Medical Institutions
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Melanoma Diagnostics and Therapeutics Market, By Cancer Type

  • 5.1 Introduction
  • 5.2 Acral Lentiginous Melanoma
  • 5.3 Amelanotic Melanoma
  • 5.4 Lentigno gna Melanoma
  • 5.5 Nodular Melanoma
  • 5.6 Superficial Spreading Melanoma
  • 5.7 Other Cancer Types

6 Global Melanoma Diagnostics and Therapeutics Market, By Diagnosis

  • 6.1 Introduction
  • 6.2 Dermatoscopy
  • 6.3 Blood Tests
  • 6.4 Computed Tomography (CT) Scan
  • 6.5 Sentinel Lymph Node Biopsy
  • 6.6 Ultrasound
  • 6.7 X-Rays
  • 6.8 Other Diagnosis

7 Global Melanoma Diagnostics and Therapeutics Market, By Therapy

  • 7.1 Introduction
  • 7.2 Chemotherapy
  • 7.3 Biological Therapy
  • 7.4 Immune Therapy
  • 7.5 Radiotherapy
  • 7.6 Targeted Therapy
  • 7.7 Other Therapies

8 Global Melanoma Diagnostics and Therapeutics Market, By Application

  • 8.1 Introduction
  • 8.2 Diagnostic Centers
  • 8.3 Hospitals
  • 8.4 Medical Institutions
  • 8.5 Other Applications

9 Global Melanoma Diagnostics and Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Diagnostics
  • 11.2 Agilent Technologies
  • 11.3 Amgen, Inc.
  • 11.4 AstraZeneca
  • 11.5 Biomerieux SA
  • 11.6 Bristol Myers Squibb
  • 11.7 Caliber Imaging & Diagnostics, Inc.
  • 11.8 Canfield Scientific, Inc.
  • 11.9 Dermlite
  • 11.10 DermTech
  • 11.11 Eli Lilly and Company
  • 11.12 Roche Holding AG
  • 11.13 GlaxoSmithKline PLC
  • 11.14 Merck & Co., Inc
  • 11.15 Novartis AG
  • 11.16 Pfizer, Inc.
  • 11.17 Qiagen
  • 11.18 Sanofi

List of Tables

  • Table 1 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Cancer Type (2021-2030) ($MN)
  • Table 3 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Acral Lentiginous Melanoma (2021-2030) ($MN)
  • Table 4 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Amelanotic Melanoma (2021-2030) ($MN)
  • Table 5 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Lentigno gna Melanoma (2021-2030) ($MN)
  • Table 6 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Nodular Melanoma (2021-2030) ($MN)
  • Table 7 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Superficial Spreading Melanoma (2021-2030) ($MN)
  • Table 8 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Cancer Types (2021-2030) ($MN)
  • Table 9 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 10 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Dermatoscopy (2021-2030) ($MN)
  • Table 11 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 12 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Computed Tomography (CT) Scan (2021-2030) ($MN)
  • Table 13 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Sentinel Lymph Node Biopsy (2021-2030) ($MN)
  • Table 14 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Ultrasound (2021-2030) ($MN)
  • Table 15 Global Melanoma Diagnostics and Therapeutics Market Outlook, By X-Rays (2021-2030) ($MN)
  • Table 16 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 17 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Therapy (2021-2030) ($MN)
  • Table 18 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Chemotherapy (2021-2030) ($MN)
  • Table 19 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Biological Therapy (2021-2030) ($MN)
  • Table 20 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Immune Therapy (2021-2030) ($MN)
  • Table 21 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Radiotherapy (2021-2030) ($MN)
  • Table 22 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Targeted Therapy (2021-2030) ($MN)
  • Table 23 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Therapies (2021-2030) ($MN)
  • Table 24 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Application (2021-2030) ($MN)
  • Table 25 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 26 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Medical Institutions (2021-2030) ($MN)
  • Table 28 Global Melanoma Diagnostics and Therapeutics Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.